Progress of Single-Cell RNA Sequencing Technology in Myocardial Infarction Research

Lanfang Li, Min Wang, Qiuxiao Ma, Yunxiu Li, Jingxue Ye, Xiaobo Sun, Guibo SunFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

This review highlights how single-cell RNA sequencing (scRNA-seq) is transforming myocardial infarction (MI) research by shifting focus from "bulk" tissue averages to the behavior of individual cells. By mapping the distinct trajectories of cardiomyocytes, immune cells, and fibroblasts during heart repair, researchers are identifying high-resolution therapeutic targets that were previously invisible.

What Problem Does This Paper Address?

Myocardial infarction (heart attack) triggers a chaotic "orchestra" of cellular events: cell death, a massive inflammatory surge, fibroblast activation (scarring), and eventually, the growth of new blood vessels (angiogenesis).

Historically, researchers used "bulk" RNA sequencing, which grinds up heart tissue and measures the average gene expression. The problem? This masks the "rare players"—the small populations of cells that might be the key to regeneration—and ignores the fact that two cells of the same type might be doing completely different things. This paper reviews how single-cell technologies allow us to zoom in on these individual "players" to understand the molecular mechanisms of heart failure and repair.

Methods

As a review article, the paper synthesizes the current state of the art in the field rather than proposing a single new algorithm. Key methodologies discussed include:

  • scRNA-seq Platforms: Comparison of droplet-based (10X Genomics) vs. plate-based (SMART-seq) methods for capturing transcriptomes.
  • snRNA-seq (Single-Nucleus Sequencing): A critical adaptation for heart research. Adult cardiomyocytes are often too large or fragile for standard microfluidic "cell" capture; sequencing just the nucleus allows researchers to study these cells without destroying them.
  • Bioinformatics Pipelines: The use of pseudo-time analysis to "watch" cells transition from one state to another (e.g., a resting fibroblast becoming an active myofibroblast) and ligand-receptor analysis to map how different cell types "talk" to each other across the injury site.

Datasets

The authors summarize findings from over a dozen major studies (compiled in Table 1).

  • Species: Primarily mouse models (ventricles and infarcted areas) at various time points (1 day to 30 days post-MI).
  • Human Data: References to the "Human Heart Atlas" projects, which have analyzed ~500,000 cells/nuclei across different cardiac regions to understand baseline heterogeneity and disease states.
  • Cell-Specific Sets: Targeted datasets focusing on non-cardiomyocytes (immune cells and fibroblasts) to identify rare sub-populations like the $CD72^{hi}$ pro-inflammatory macrophages.

Key Insights and Ideas

  • The Myofibroblast Spectrum: Instead of a simple "on/off" switch for scarring, scRNA-seq reveals that fibroblasts exist in a continuous, shifting landscape of phenotypes. Some are purely inflammatory, while others (like those expressing Cthrc1) are essential for preventing heart rupture.
  • Cardiomyocyte Plasticity: While adult heart cells generally don't divide, scRNA-seq has identified rare subsets of cardiomyocytes that "de-differentiate" to a more fetal-like state after injury, offering a potential window for induced regeneration.
  • Immune "Training": The paper discusses how macrophages aren't just "good" or "bad" but are highly plastic. Specific subsets recruited from the bone marrow have vastly different transcriptional profiles than resident heart macrophages.
  • Angiogenesis Regulators: The discovery of ZEB2 and Plvap as specific markers/regulators of endothelial cells that help rebuild the vascular network after an ischemic event.

Key Results

  • High-Resolution Mapping: Studies have successfully identified at least seven distinct macrophage subsets and multiple fibroblast states that appear only after MI.
  • Regenerative Windows: scRNA-seq confirmed that neonatal mice can regenerate heart tissue via cardiomyocyte proliferation, whereas adult mice switch to a fibrotic (scarring) program—identifying the specific transcription factors (like NFYa) that drive this difference.
  • Direct Reprogramming: Researchers are using single-cell data to improve "cardiac reprogramming"—the attempt to turn scar-forming fibroblasts directly into functional heart muscle cells—by identifying the molecular "roadblocks" that cause cells to get stuck in intermediate, non-functional states.

Limitations and Future Work

The authors acknowledge several "bottlenecks" that the field must overcome:

  • The RNA-Protein Gap: Transcript levels (RNA) don't always correlate with protein levels, which are the actual functional units of the cell. Future work needs to integrate proteomics.
  • Spatial Context: Standard scRNA-seq requires dissociating tissue, which loses the "map" of where cells were located. The authors point toward spatial transcriptomics as the next frontier to see how cells interact in their native neighborhood.
  • Sequencing Depth: Current methods often only capture a fraction of the total transcripts in a cell, potentially missing low-abundance signaling molecules.
  • Clinical Translation: Most data is currently from mice. There is an urgent need for more high-quality human single-cell data to ensure these "targets" actually work in patients.

Summary updated

Abstract

After myocardial infarction, the heart enters a remodeling and repair phase that involves myocardial cell damage, inflammatory response, fibroblast activation, and, ultimately, angiogenesis. In this process, the proportions and functions of cardiomyocytes, immune cells, fibroblasts, endothelial cells, and other cells change. Identification of the potential differences in gene expression among cell types and/or transcriptome heterogeneity among cells of the same type greatly contribute to understanding the cellular changes that occur in heart and disease conditions. Recent advent of the single-cell transcriptome sequencing technology has facilitated the exploration of single cell diversity as well as comprehensive elucidation of the natural history and molecular mechanisms of myocardial infarction. In this manner, novel putative therapeutic targets for myocardial infarction treatment may be detected and clinically applied.
BibTeX
@inproceedings{li2022progress,
  author = {Lanfang Li and Min Wang and Qiuxiao Ma and Yunxiu Li and Jingxue Ye and Xiaobo Sun and Guibo Sun},
  title = {{Progress of Single-Cell RNA Sequencing Technology in Myocardial Infarction Research}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.768834},
}
Figure